Ataibeckley Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Ataibeckley Inc 's ROA in the second quarter of 2026?
Ataibeckley Inc recorded a cumulative net loss of $-668 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -251.38%.

However, within the Healthcare sector 874 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4548, from total ROA ranking in the first quarter of 2026 at 5265.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	37.93 %	34.3 %	82.59 %	21.2 %	-11.6 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-668	-663	-660	-154	-120
Return On Assets (TTM)	-251.38 %	-267.92 %	-286.12 %	-78.08 %	-63.88 %
ATAI's Total Ranking	# 4548	# 5265	# 4284	# 4231	# 4401
Total Assets (TTM) in million	265	265	293	241	192
Seq. Total Assets Change	-0.03 %	-9.51 %	21.47 %	25.52 %	-2.66 %
Seq. Net Income Change	-	-	-	-	-

ATAI's 5 Years Annual ROA >> Back to ATAI Management Effectiveness >> Compare ATAI ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 418
Sector	# 875
Overall	# 4484

Return On Assets Statistics
High	Average	Low
-5.32 %	-77.5 %	-287.79 %
(Jun 30 2022)		(Dec 31 2025)

Financial Statements
Ataibeckley Inc 's Assets	$ 265 million	ATAI's Balance sheet
Ataibeckley Inc 's Income	$ -33 million	Quarterly ATAI's Income Statement
ATAI's Income by Division		See ATAI's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	82.59 %	-45.7 %	-1.54 %	-26.93 %	-
Total Assets in million	293	160	295	300	410
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-660	-150	-44	-157	-174
Annual Return On Assets	-225.52 %	-93.6 %	-14.87 %	-52.5 %	-42.46 %

ATAI's 5 Years Annual ROA >> Back to ATAI Management Effectiveness >> Compare ATAI ROA to its Competitors

More Return On Assets Ratios
ATAI's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ATAI's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ATAI's Competitors
Subscribers only: Roa for Ataibeckley Inc 's Suppliers
Subscribers only: Return On Assets for ATAI's Customers

You may also want to know
ATAI's Roi	ATAI's Inventory Turnover Ratio	ATAI's Growth Rates	ATAI's Dividend Comparisons
	ATAI's Profitability Ratios	ATAI's Asset Turnover Ratio	ATAI's Dividend Growth
ATAI's Roe	ATAI's Valuation Ratios	ATAI's Financial Strength Ratios	ATAI's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:43:40+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.